{"organizations": [], "uuid": "ed35e799b9f3f0e4ad1bbb818b55091b6cc6c003", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 9, "shares": 9, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources/r/?m=02&d=20180226&t=2&i=1235318917&w=1200&r=LYNXNPEE1P1EY", "site_section": "http://feeds.reuters.com/reuters/businessNews", "section_title": "Reuters: Business News", "url": "https://www.reuters.com/article/us-mimedx-group-probe/u-s-justice-dept-probing-mimedxs-business-practices-bloomberg-idUSKCN1GA26F", "country": "US", "domain_rank": 408, "title": "U.S. Justice Dept probing MiMedx's business practices: Bloomberg", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-26T18:52:00.000+02:00", "replies_count": 0, "uuid": "ed35e799b9f3f0e4ad1bbb818b55091b6cc6c003"}, "author": "", "url": "https://www.reuters.com/article/us-mimedx-group-probe/u-s-justice-dept-probing-mimedxs-business-practices-bloomberg-idUSKCN1GA26F", "ord_in_thread": 0, "title": "U.S. Justice Dept probing MiMedx's business practices: Bloomberg", "locations": [], "entities": {"persons": [{"name": "mimedx", "sentiment": "negative"}, {"name": "manas mishra", "sentiment": "none"}, {"name": "maju samuel", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "justice dept", "sentiment": "negative"}, {"name": "bloomberg", "sentiment": "negative"}, {"name": "u.s. justice dept", "sentiment": "negative"}, {"name": "mimedx group inc", "sentiment": "none"}, {"name": "u.s. justice department", "sentiment": "none"}, {"name": "mimedx", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "bloomberg reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Reuters) - Regenerative medicine maker MiMedx Group Inc ( MDXG.O ) is under federal investigation related to two business practices, Bloomberg reported on Monday, citing people familiar with the matter. \nThe company’s shares fell as much as 22.7 percent to a more than three-and-a-half year low of $6.05. \nThe U.S. Justice Department is probing whether MiMedx overcharged the government for its tissue repair products, as well as into the company’s distribution practices, the Bloomberg report said. \nThe company did not immediately respond to Reuters’ queries. \nLast week, the company said independent advisers were looking into certain sales and distribution practices at the company, and postponed its fourth-quarter financial results. \nUp to Friday’s close, the company’s shares had fallen nearly 40 percent this year. \nReporting by Manas Mishra in Bengaluru; Editing by Maju Samuel\n ", "external_links": [], "published": "2018-02-26T18:52:00.000+02:00", "crawled": "2018-02-26T19:08:45.012+02:00", "highlightTitle": ""}